Guardant Health, Inc. (NASDAQ:GH) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET

Company Participants

Alex Kleban – Vice President-Investor Relations

Helmy Eltoukhy – Chairman and Co-Chief Executive Officer

AmirAli Talasaz – Co-Chief Executive Officer

Mike Bell – Chief Financial Officer

Conference Call Participants

Dan Arias – Stifel

Max Masucci – Cowen

Tejas Savant – Morgan Stanley

Derik De Bruin – Bank of America

Jack Meehan – Nephron

Julia Qin – JPMorgan

Puneet Souda – SVB Securities

Matt Sykes – Goldman Sachs

Dan Leonard – Credit Suisse

Patrick Donnelly – Citi

Operator

Thank you for standing by, and welcome to the Guardant Health Fourth Quarter and Full Year 2022 Financial Results Call. My name is Sam, and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call. [Operator Instructions]

I'll now turn the call over to Alex Kleban. Alex, please go ahead.

Alex Kleban

Thank you. Earlier today, Guardant Health released financial results for the quarter and year ended December 31, 2022. Joining me today from Guardant are Helmy Eltoukhy, Co-CEO; AmirAli Talasaz, Co-CEO; and Mike Bell, Chief Financial Officer.

Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled forward-looking statements in the press release Guardant issued today. For a more complete list and description, please see the Risk Factors section of the company's annual report on Form 10-K for the year ended December 31, 2022 and in its other filings with the Securities and Exchange Commission.

This call will also include a discussion of certain financial measures that are not calculated in accordance with GAAP. Reconciliations to the most directly comparable GAAP financial measure may be found in today's earnings release submitted to the SEC. Except as required by law, Guardant disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, February 23, 2023.

With that, I'd like to turn the call over to Helmy.

Helmy Eltoukhy

Thanks, Alex. Good afternoon, and thank you for joining our fourth quarter and full year 2022 earnings call. I will start off our call today by providing an update on our progress over 2022 and go into more detail across our oncology business. I will then turn the call over to AmirAli for an update on our screening business. And finally, Mike will provide a more detailed look at our financials and outlook for 2023.